Likewise, in recent studies, HE4, which is a serum biomarker currently used to monitor the recurrence of epithelial ovarian cancer, has been demonstrated to be strongly associated with HF and it seems to represent an independent predictor of HF outcomes [70,71,72]. This evidence concerns the gene WFDC2 and hydrops fetalis.